

# Mercia Asset Management

FY19 results

Scaling regional powerhouse

Investment companies

Mercia's FY19 results reflect continued progress across the portfolio, with the company in good shape for further growth. Net assets rose 2% to £126.1m, but FUM fell 5% to £381m due to the winding up of the successful RisingStars Growth Fund (15% IRR, TVPI of 528%). The direct investment portfolio increased to £87.7m, with £19.4m of cash invested in 17 companies, as well as £3.9m of fair value uplift. Mercia remains well positioned for further progress in FY20 with key portfolio companies strategically well placed, together with firepower from the group's £168m of free cash and £30m of unrestricted balance sheet cash. The shares continue to trade at a significant discount to NAV (0.77x), even before considering the embedded value of Mercia Fund Managers (10p+).

Period end	Net cash* (£m)	Direct investments (£m)	FUM (£m)	NAV (£m)	NAV per share (p)	P/NAV (x)
03/16	30.9	38.1	220.0	80.0	26.4	1.20
03/17	59.6	52.0	336.5	121.4	40.0	0.79
03/18	49.4	66.1	400.0	123.5	40.7	0.78
H119	38.3	77.8	394.9	125.2	41.3	0.77
03/19	29.8	87.7	381.0	126.1	41.6	0.77

Note: \*Includes liquid securities but not funds held on behalf of EIS investors.

# 32.7% growth in direct investment portfolio

Mercia reported FY19 net assets of £126.1m (FY18: £123.5m). The direct investment portfolio grew by 32.7% to £87.7m. In Mercia Fund Managers, FUM fell 5% to £381m with the winding up of the successful RisingStars Growth Fund (15% IRR, TVPI of 528%). Net expenses rose to £1.4m (FY18: £0.4m), largely due to a one-off performance-related fee received in FY18, and staff and administrative expenses rose 13.9% as headcount was expanded to manage mandates won in FY18. Management reiterated its intention to achieve a sustainable position in the medium term, where revenue covers expenses before realised gains and fair value movements.

# **Brand repositioning: Mercia Asset Management**


Mercia has changed its name to Mercia Asset Management to better reflect the balance of the business. Its stated intent remains to become the leading regional provider of supportive balance sheet, venture, private equity and debt capital in transaction sizes typically below £10m. Historically, Mercia has been closely associated with IP commercialisation. However, this categorisation no longer reflects the growth of the business, the diversity of its deal sourcing or the breadth of its investment portfolio, both debt and equity. IP commercialisation remains an important element of Mercia's investment proposition, but today represents one of five principal sources of deal flow.

#### Valuation: 0.77x NAV, does not include MFM

Mercia's shares continue to trade at a discount to NAV (0.77x), even before considering the embedded value of Mercia Fund Managers, which we believe should add 10p+ to NAV. Catalysts for a re-rating include meaningful commercialisation of the direct investment portfolio and/or further successful exits.

	8 July 2019
Price	31.8p
Market cap	£96m
Net cash (£m) at 31 March 2019	29.8
Shares in issue	303.3m
Free float	47.3%
Code	MERC
Primary exchange	AIM
Secondary exchange	N/A

# Share price performance



#### **Business description**

Mercia Asset Management is a regionally focused specialist asset manager. Its stated intent is to become the leading regional provider of supportive balance sheet, venture, private equity and debt capital in transaction sizes typically below £10m.

Next event	
AGM	September 2019
Half year results	December 2019
Analysts	
Richard Williamson	+44 (0)20 3077 5700
Victoria Pease	+44 (0)20 3077 5700
tech@edisongroup.com	
Edison profile page	

Mercia Asset Management is a research client of Edison Investment Research Limited



#### FY19 results review

#### Small rise in net assets

Mercia reported a net asset value of £126.1m at end FY19 (vs £123.5m at end FY18) or 41.6p per share (FY18: 40.7p), representing a small rise of 2% over the year. Direct investment of £19.4m was made into 17 portfolio companies (FY18: £21.1m, 17 companies) during the year, including two new direct investments, W2 Global Data Solutions and Locate Bio. Largely as a result of the £19.4m of direct investment, unrestricted cash and short-term liquidity investments fell from £49.4m at end FY18 to £29.8m at end FY19, in line with management guidance.

Funds under management (FUM) fell by 4.8% to £381.3m, from £400m at FY18. This fall in FUM was largely attributable to the winding up of the successful RisingStars Growth Fund, an early-stage fund that generated an investor IRR of 15% over its lifetime, total value to paid-in capital (TVPI) of 528% and distributions as a proportion of paid in capital (DPI) of 468%. The demonstrable success of this fund and the returns delivered to investors positions the group well to raise further funds in the future.

Group revenues increased by 4.7% to £10.7m (FY18: £10.2m), largely due to the full year contribution from fund management contracts won during FY18, split £7.3m from fund management fees, £1.1m from initial management fees and £2.1m from portfolio director fees. The prior year comparison was also flattered by a one-off £1.2m performance-related fund management fee.

Net expenses rose to £1.4m (FY18: £0.4m) due to the one-off performance-related fee, and staff and admin expenses of 13.9% to £12.1m (FY18: £10.6m), reflecting an increase in headcount (from 65 to 85 over the course of the year) required to manage the FY18 fund mandate wins. Management expects net expenses to level off for FY20. Management also reiterated its intention to achieve a sustainable zero net expenses position in the medium term, where revenues cover expenses before realised gains and fair value movements, to minimise NAV erosion.

#### Portfolio review: Direct investment up 32.7% vs prior year

Mercia's direct investment portfolio grew from £66.1m in FY18 to £87.7m in FY19, with net portfolio investment of £17.7m (£19.4m less a £1.7m loan repayment), together with a fair value increase of £3.9m (FY18: £2.8m). Like previous reporting periods, Mercia's top 20 direct investments represented 98.4% of total portfolio value.

Notable fair value uplifts included: nDreams (£1.1m); Intelligent Positioning (£1.3m); Faradion (£1.6m); Oxford Genetics (£0.6m); Medherant (£1.2m); The Native Antigen Company (£0.9m); and Voxpopme (£0.5m). On the downside, as well as the fair value write-off of Smart Antenna Technologies, Mercia also reflected a negative fair value movement of £0.5m on Concepta, recognising market movements on the AIM listed investment. A previous fair value provision for Soccer Manager was released as the company's prospects were deemed to have materially improved with an acceleration in revenues, following Mercia's proactive intervention.

Post year-end developments are as follows:

- Further funding rounds for Voxpopme (£1.3m), Medherant (£1.5m) and Locate Bio (£1.8m).
- £0.8m investment into MyLotus developer, Concepta, as part of a £2.3m placing in April 2019.
- £0.5m invested into a new direct investment, Clear Review, a fast-growing SaaS business providing HR management tools.
- nDreams announced a partnership with global technology company Oculus (Facebook), developing its first title – Phantom: Covert Ops. This received significant industry recognition including the Game Critics Award for the best VR/AR game at the E3 Expo in June 2019.



D.35 (4) 众 口

Exhibit 1: nDreams - Oculus partnership for Phantom: Covert Ops

Source: nDreams, YouTube

Note								
Note	Exhibit 2: Direct investm	ent portfolio						
Oxford Genetics         Life sciences/biosciences         9,090         9,090         433         638         10,161         33           Warwick Acoustics         EMME         6,152         7,152         1,500         252         7,904         66           Intechnica         Software and the internet         4,021         4,677         2,000         656         6,677         33           Ton UK t/a Intelligent Positioning         Software and the internet         4,216         4,216         -         1,257         5,473         21           Impression Technologies         EMME         3,107         4,607         2,268         6         5,381         3           Medherant         Life sciences/biosciences         3,453         3,453         524         1,228         5,205         3           VirtTrade t/a Avid Games         Digital/digital entertainment         2,538         3,088         1,400         -         3,938         22           Faradion         EMME         1,299         3,524         601         1,625         3,525         18           Voxpopme         Software and the internet         1,000         3,026         1,500         526         3,026         2           The Native Antigen Company<	£000s	Sector			invested	change		% held at 31/3/19
Warwick Acoustics         EMME         6,152         7,152         1,500         252         7,904         66           Intechnica         Software and the internet         4,021         4,677         2,000         656         6,677         33           Ton UK t/a Intelligent Positioning         Software and the internet         4,216         4,216         -         1,257         5,473         20           Impression Technologies         EMME         3,107         4,607         2,268         6         5,381         3           Medherant         Life sciences/biosciences         3,453         3,453         524         1,228         5,205         3           VirtTrade t/a Avid Games         Digital/digital entertainment         2,538         3,088         1,400         -         3,938         26           Faradion         EMME         1,299         3,524         601         1,625         3,525         16           Voxpopme         Software and the internet         1,000         3,026         1,500         526         3,026         2           The Native Antigen Company         Life sciences/biosciences         1,942         2,324         -         921         2,863         33           PsiOxus Therapeutic	nDreams	Digital/digital entertainment	12,979	12,979	1,029	1,112	15,120	45.5
Intechnica	Oxford Genetics	Life sciences/biosciences	9,090	9,090	433	638	10,161	33.3
Ton UK t/a Intelligent Positioning         Software and the internet         4,216         4,216         -         1,257         5,473         22           Impression Technologies         EMME         3,107         4,607         2,268         6         5,381         3           Medherant         Life sciences/biosciences         3,453         3,453         524         1,228         5,205         3           VirtTrade t/a Avid Games         Digital/digital entertainment         2,538         3,088         1,400         -         3,938         24           Faradion         EMME         1,299         3,524         601         1,625         3,525         18           Voxpopme         Software and the internet         1,000         3,026         1,500         526         3,026         2           The Native Antigen Company         Life sciences/biosciences         1,942         2,324         -         921         2,863         33           PsiOxus Therapeutics         Life Sciences/biosciences         2,377         2,377         -         -         2,377           Edge Case Games         Digital/digital entertainment         2,000         3,150         300         -         2,300         2           Soccer Manager <td>Warwick Acoustics</td> <td>EMME</td> <td>6,152</td> <td>7,152</td> <td>1,500</td> <td>252</td> <td>7,904</td> <td>62.5</td>	Warwick Acoustics	EMME	6,152	7,152	1,500	252	7,904	62.5
Impression Technologies	Intechnica	Software and the internet	4,021	4,677	2,000	656	6,677	32.0
Medherant         Life sciences/biosciences         3,453         3,453         524         1,228         5,205         3           VirtTrade t/a Avid Games         Digital/digital entertainment         2,538         3,088         1,400         -         3,938         26           Faradion         EMME         1,299         3,524         601         1,625         3,525         16           Voxpopme         Software and the internet         1,000         3,026         1,500         526         3,026         2           The Native Antigen Company         Life sciences/biosciences         1,942         2,324         -         921         2,863         3           PsiOxus Therapeutics         Life Sciences/biosciences         2,377         2,377         -         -         2,377         -         -         2,377         -         -         2,377         -         -         2,377         -         -         2,377         -         -         2,377         -         -         2,300         2         2         3,000         -         2,300         2         2         3,000         -         2,300         2         3,000         -         2,300         2         3,000         -         2,00	Ton UK t/a Intelligent Positioning	Software and the internet	4,216	4,216	-	1,257	5,473	28.8
VirtTrade t/a Avid Games         Digital/digital entertainment         2,538         3,088         1,400         -         3,938         20           Faradion         EMME         1,299         3,524         601         1,625         3,525         18           Voxpopme         Software and the internet         1,000         3,026         1,500         526         3,026         2           The Native Antigen Company         Life sciences/biosciences         1,942         2,324         -         921         2,863         33           PsiOxus Therapeutics         Life Sciences/biosciences         2,377         2,377         -         -         2,377           Edge Case Games         Digital/digital entertainment         2,000         3,150         300         -         2,300         2           Soccer Manager         Digital/digital entertainment         1,199         1,499         500         400         2,099         3           W2 Global Data Solutions         Software and the internet         -         -         2,000         -         2,000         1           LM Technologies         EMME         1,913         1,913         -         -         1,913         4           sureCore         EMME	Impression Technologies	EMME	3,107	4,607	2,268	6	5,381	31.4
Faradion         EMME         1,299         3,524         601         1,625         3,525         18           Voxpopme         Software and the internet         1,000         3,026         1,500         526         3,026         2           The Native Antigen Company         Life sciences/biosciences         1,942         2,324         -         921         2,863         33           PsiOxus Therapeutics         Life Sciences/biosciences         2,377         2,377         -         -         2,377         -         -         2,377         -         -         2,377         -         -         2,377         -         -         2,377         -         -         2,377         -         -         2,377         -         -         2,377         -         -         2,377         -         -         2,377         -         -         2,300         2         -         2,300         2         -         2,300         2         -         2,300         2         -         2,000         -         2,000         -         2,000         -         2,000         -         2,000         -         2,000         -         2,000         -         2,000         -         1,913	Medherant	Life sciences/biosciences	3,453	3,453	524	1,228	5,205	31.9
Voxpopme         Software and the internet         1,000         3,026         1,500         526         3,026         2           The Native Antigen Company         Life sciences/biosciences         1,942         2,324         -         921         2,863         33           PsiOxus Therapeutics         Life Sciences/biosciences         2,377         2,377         -         -         2,377         -         2,377         -         -         2,377         -         -         2,377         -         -         2,377         -         -         2,377         -         -         2,377         -         -         2,377         -         -         2,377         -         -         2,377         -         -         2,377         -         -         2,300         2         -         2,300         2         -         2,300         2         -         2,300         2         -         2,000         -         2,000         -         2,000         -         2,000         -         2,000         -         2,000         -         2,000         -         2,000         -         2,000         -         2,000         -         1,913         1,913         -         -         1,9	VirtTrade t/a Avid Games	Digital/digital entertainment	2,538	3,088	1,400	-	3,938	28.4
The Native Antigen Company         Life sciences/biosciences         1,942         2,324         -         921         2,863         33           PsiOxus Therapeutics         Life Sciences/biosciences         2,377         2,377         -         -         2,377           Edge Case Games         Digital/digital entertainment         2,000         3,150         300         -         2,300         2           Soccer Manager         Digital/digital entertainment         1,199         1,499         500         400         2,099         3           W2 Global Data Solutions         Software and the internet         -         -         -         2,000         -         2,000         1           LM Technologies         EMME         1,913         1,913         -         -         1,913         4           sureCore         EMME         1,500         1,834         334         -         1,834         24           Aston EyeTech t/a Eyoto         Life sciences/biosciences         1,750         1,750         4         1         1,755         18           Crowd Reactive         Software and the internet         1,650         1,637         (61)         -         1,589         20           Concepta         Life	Faradion	EMME	1,299	3,524	601	1,625	3,525	18.1
PsiOxus Therapeutics         Life Sciences/biosciences         2,377         2,377         -         -         2,377           Edge Case Games         Digital/digital entertainment         2,000         3,150         300         -         2,300         2           Soccer Manager         Digital/digital entertainment         1,199         1,499         500         400         2,099         3           W2 Global Data Solutions         Software and the internet         -         -         2,000         -         2,000         1           LM Technologies         EMME         1,913         1,913         -         -         1,913         4           sureCore         EMME         1,500         1,834         334         -         1,834         24           Aston EyeTech t/a Eyoto         Life sciences/biosciences         1,750         1,750         4         1         1,755         18           Crowd Reactive         Software and the internet         1,650         1,637         (61)         -         1,589         26           Concepta         Life sciences/biosciences         1,306         1,203         365         (538)         1,133         18           Locate Bio         Life sciences/biosciences	Voxpopme	Software and the internet	1,000	3,026	1,500	526	3,026	21.8
Edge Case Games         Digital/digital entertainment         2,000         3,150         300         -         2,300         2           Soccer Manager         Digital/digital entertainment         1,199         1,499         500         400         2,099         3           W2 Global Data Solutions         Software and the internet         -         -         2,000         -         2,000         1           LM Technologies         EMME         1,913         1,913         -         -         1,913         4           sureCore         EMME         1,500         1,834         334         -         1,834         24           Aston EyeTech t/a Eyoto         Life sciences/biosciences         1,750         1,750         4         1         1,755         18           Crowd Reactive         Software and the internet         1,650         1,637         (61)         -         1,589         26           Concepta         Life sciences/biosciences         1,306         1,203         365         (538)         1,133         18           Locate Bio         Life sciences/biosciences         -         -         500         -         500         -         500	The Native Antigen Company	Life sciences/biosciences	1,942	2,324	-	921	2,863	32.7
Soccer Manager         Digital/digital entertainment         1,199         1,499         500         400         2,099         33           W2 Global Data Solutions         Software and the internet         -         -         2,000         -         2,000         11           LM Technologies         EMME         1,913         1,913         -         -         1,913         4           sureCore         EMME         1,500         1,834         334         -         1,834         24           Aston EyeTech t/a Eyoto         Life sciences/biosciences         1,750         1,750         4         1         1,755         18           Crowd Reactive         Software and the internet         1,650         1,637         (61)         -         1,589         26           Concepta         Life sciences/biosciences         1,306         1,203         365         (538)         1,133         18           Locate Bio         Life sciences/biosciences         -         -         500         -         500         -         500	PsiOxus Therapeutics	Life Sciences/biosciences	2,377	2,377	-	-	2,377	1.5
W2 Global Data Solutions         Software and the internet         -         -         2,000         -         2,000         1           LM Technologies         EMME         1,913         1,913         -         -         1,913         4           sureCore         EMME         1,500         1,834         334         -         1,834         24           Aston EyeTech t/a Eyoto         Life sciences/biosciences         1,750         1,750         4         1         1,755         18           Crowd Reactive         Software and the internet         1,650         1,637         (61)         -         1,589         26           Concepta         Life sciences/biosciences         1,306         1,203         365         (538)         1,133         18           Locate Bio         Life sciences/biosciences         -         -         500         -         500         -	Edge Case Games	Digital/digital entertainment	2,000	3,150	300	-	2,300	21.2
LM Technologies         EMME         1,913         1,913         -         -         1,913         4           sureCore         EMME         1,500         1,834         334         -         1,834         24           Aston EyeTech t/a Eyoto         Life sciences/biosciences         1,750         1,750         4         1         1,755         18           Crowd Reactive         Software and the internet         1,650         1,637         (61)         -         1,589         26           Concepta         Life sciences/biosciences         1,306         1,203         365         (538)         1,133         18           Locate Bio         Life sciences/biosciences         -         -         500         -         500         -         500	Soccer Manager	Digital/digital entertainment	1,199	1,499	500	400	2,099	31.6
sureCore         EMME         1,500         1,834         334         -         1,834         22           Aston EyeTech t/a Eyoto         Life sciences/biosciences         1,750         1,750         4         1         1,755         18           Crowd Reactive         Software and the internet         1,650         1,637         (61)         -         1,589         26           Concepta         Life sciences/biosciences         1,306         1,203         365         (538)         1,133         18           Locate Bio         Life sciences/biosciences         -         -         500         -         500         -         500	W2 Global Data Solutions	Software and the internet	-	-	2,000	-	2,000	17.4
Aston EyeTech t/a Eyoto         Life sciences/biosciences         1,750         1,750         4         1         1,755         18           Crowd Reactive         Software and the internet         1,650         1,637         (61)         -         1,589         26           Concepta         Life sciences/biosciences         1,306         1,203         365         (538)         1,133         18           Locate Bio         Life sciences/biosciences         -         -         500         -         500         -         500	LM Technologies	EMME	1,913	1,913	-	-	1,913	41.4
Crowd Reactive         Software and the internet         1,650         1,637         (61)         -         1,589         26           Concepta         Life sciences/biosciences         1,306         1,203         365         (538)         1,133         18           Locate Bio         Life sciences/biosciences         -         -         500         -         500         6	sureCore	EMME	1,500	1,834	334	-	1,834	24.4
Concepta         Life sciences/biosciences         1,306         1,203         365         (538)         1,133         18           Locate Bio         Life sciences/biosciences         -         -         500         -         500         6	Aston EyeTech t/a Eyoto	Life sciences/biosciences	1,750	1,750	4	1	1,755	18.7
Locate Bio Life sciences/biosciences 500 - 500	Crowd Reactive	Software and the internet	1,650	1,637	(61)	-	1,589	26.2
	Concepta	Life sciences/biosciences	1,306	1,203	365	(538)	1,133	18.2
Smart Antenna Technologies FMMF 2 148 3 348 1 900 (4 048) - 33	Locate Bio	Life sciences/biosciences	-	-	500	-	500	6.0
2,110 0,010 (7,010)	Smart Antenna Technologies	EMME	2,148	3,348	1,900	(4,048)	-	32.2
Other direct investments 430 980 576 (120) 886 r	Other direct investments		430	980	576	(120)	886	n/a
Total 66,070 77,827 17,673 3,916 87,659 r	Total		66,070	77,827	17,673	3,916	87,659	n/a

Source: Mercia. Note: EMME is Electronics, Materials, Manufacturing and Engineering. Excludes post year-end investments.

## Valuation: Mercia looks undervalued at 0.77x NAV

In line with Mercia's intent to become the leading regional provider of supportive balance sheet, venture, private equity and debt capital in transaction sizes typically below £10m, we have broadened Mercia's valuation peer group to include a broader range of direct private equity and venture capital investors, as well as IP commercialisation companies.



Mercia trades at a 23% discount to FY19 NAV, below the mean and median of the peer group and, in our view, unwarranted given the strength of the business and its underlying operating model.

	Price	Currency	Market cap (m)	NAV (m) (last reported)	Cash/(debt) (m)	NAV multiple (x)	NAV pe share (p
Allied Minds	72.7	GBP	175.0	218	40	0.80	91
Arix Bioscience	136	GBP	184.4	270	91	0.68	200
IP Group	75.1	GBP	795.4	1218	219	0.65	115
Malin Corporation	3.80	€	173.6	392	(12)	0.44	8.57
HgCapital	221.5	GBP	891.8	802	102	1.11	215
Oakley Capital	235.0	GBP	481.3	575	212	0.84	281
Draper Esprit	550.0	GBP	648.6	619	100	1.05	524
Augmentum FinTech	112.0	GBP	105.3	98	44	1.08	104
					Mean	0.83	
					Median	0.82	
Mercia	31.7	GBP	96.1	126	30	0.76	41.6
Adjustment for embedded	funds busine	SS		32			10.6
Mercia + Adjustment	31.7	GBP	96.1	158	30	0.61	52.1

#### NAV excludes the embedded funds business

Mercia's strategic goals remain to grow the value of the direct investment portfolio, while also seeking to expand FUM to allow the group to reach a sustainable position over the medium term, where revenue covers expenses before realised gains and fair value movements.

These goals underline that the NAV-based valuation does not properly reflect the embedded value of Mercia Fund Managers, whose fees already cover a significant proportion of the group's net expenses. Placing these fees on a relatively conservative 3x EV/Sales multiple implies a value of £32m or 10.6p per share for Mercia Fund Managers (from 9p based on EV/Sales and P/E previously). Adjusting the NAV calculation for this embedded value (see Exhibit 3), suggests that Mercia is trading at closer to 0.61x the group's adjusted value.

In our view, this level of discount does not reflect either the strategic positioning of the portfolio or the strength of Mercia's underlying operating model.

# **Group overview**

#### **Mercia Asset Management**

Despite the name change last week, Mercia's business model remains the same. Its stated intent is to become the leading regional provider of supportive balance sheet, venture, private equity and debt capital in transaction sizes typically below £10m.

Historically, Mercia has been closely associated with IP commercialisation. However, this categorisation no longer reflects the growth of the business, the diversity of its deal sourcing or the breadth of its investment portfolio, both debt and equity. Through its 19 university partnerships, IP commercialisation will remain an important element of Mercia's overall investment proposition, but today represents one of five principal sources of deal flow (the others being direct sourcing from Mercia's own network, client referrals, advisor referrals and cross-referrals).



Exhibit 4: Mark Payton, CEO on Mercia's FY19 results




Source: Mercia Asset Management, Edison Investment Research

#### **Funds overview**

Mercia invests in both growing its pipeline and its existing portfolio companies through four pools of capital under management: balance sheet (£87.7m portfolio fair value, £30m unrestricted cash), venture (FUM £224.1m), private equity (£61.2m) and debt (£96.0m). In aggregate, the company manages assets under management (AUM) of c £500m, of which FUM accruing management fees represent £381m.

We include below introductory snapshots from the Fund Principals for each of for each of Mercia's three main business lines. Venture, including EIS and IP commercialisation, represents the majority (FY19: 59%) of the group's funds under management, but private equity (16%) and debt (25%) together represent a substantial proportion of overall funds.

Exhibit 5: Split of funds under management (FUM)



Source: Mercia Asset Management, Edison Investment Research

#### Fund performance and returns

To date, Mercia's closed and legacy funds have returned c £177m, with vintages varying from 10 to 16 years and with typical IRRs of 15–17%.



#### Venture - FUM £224.1m

Venture capital remains an important source of funding for entrepreneurial start-ups and young, growing companies. Mercia is one of the leading providers of venture capital and equity funding to small businesses in the UK regions, providing funding in the range of £0.05–2m across all sectors of the UK economy.



Source: Mercia Asset Management, Edison Investment Research

## Private equity - FUM £61.2m

Through its EV Growth Funds, Mercia is one of the most active investors backing management teams looking to scale. It offers equity investment of up to £5m for purposes including expansion finance, to support management buyouts and buy-ins, acquisition finance, cash-out transactions and preparing for succession planning.

Mercia structures packages of debt and equity that deliver returns through a combination of yield, performance-related dividends and capital gain on exit, typically over a period of three to five years.



Source: Mercia Asset Management, Edison Investment Research

#### Debt - FUM £96.0m

Mercia provides debt funding ranging from £0.1m to £1m to both start-up and established businesses, across all sectors to businesses based anywhere in the UK.

Debt is available for a wide range of purposes: additional working capital to fund expansion plans, cover the cost of fulfilling a new contract or buying stock. Alternatively, businesses may need to borrow money to acquire a new property, improve existing premises or invest in plant machinery, new IT systems or other one-off business expenses. Mercia can often help in situations where banks and other lenders are unable to provide the full requirement.

Packages are tailored to individual business requirements with competitive rates and terms. Funding is typically for a period of up to five years, with rates fixed for the duration.

Exhibit 8: Paul Taberner, Fund Principal – Debt

Paul Taberner
Fund Principle - Debt, Mercia Technologies

No. 2011

Source: Mercia Asset Management, Edison Investment Research



	£'000 2015	2016	2017	2018	2019
31-March	IFRS	IFRS	IFRS	IFRS	IFR
INCOME STATEMENT					
Revenue	508	1,755	6,660	10,197	10,67
Cost of Sales	(10)	(79)	(92)	0	
Gross Profit	498	1,676	6,568	10,197	10,67
Operating costs	(1,495)	(4,011)	(9,051)	(10,633)	(12,115
Fair value changes	3,934	896	4,268	2,823	3,91
Realised gains	0	0	839	871	0.47
Normalised operating profit	2,937	(1,439)	2,624	3,258	2,470
Amortisation of acquired intangibles	(4.040)	(17)	(301)	(301)	(301
Exceptionals Chara based payments	(1,018)	(372)	(1,125)	(1,125)	/171
Share-based payments	(44) 1,875	(230)	(395)	(497) 1,335	(171
Reported operating profit  Net Interest	93	(2,058)	186	274	2,00 56
Joint ventures & associates (post tax)	0	0	0	0	30.
Profit Before Tax (norm)	3,030	(1,078)	2,810	3,532	3,03
Profit Before Tax (right)	1,968	(1,697)	989	1,609	2,56
Reported tax	0	(1,097)	54	54	2,30
Profit After Tax (norm)	3,030	(1,078)	2,810	3,532	3,03
Profit After Tax (norm) Profit After Tax (reported)	1,968		1,043	1,663	2,62
Minority interests	1,968	(1,697) 0	1,043	0	2,02
Discontinued operations	0	0	0	0	
Discontinued operations  Net income (normalised)	3,030		2,810	3,532	3,03
Net income (normalised) Net income (reported)	3,030 1,968	(1,078)	1,043	3,532 1,663	2,62
		(1,697)			
Basic average number of shares outstanding (m)	212	212	224	302	30:
EPS - basic normalised (p)	1.43	(0.51)	1.26	1.17	1.0
EPS - diluted normalised (p)	1.43	(0.51)	1.21	1.13	0.9
EPS - basic reported (p)	0.93	(0.80)	0.47	0.55	0.8
Dividend (p)	0.00	0.00	0.00	0.00	0.0
Revenue growth (%)	(-29.7)	245.5	279.5	53.1	4.
Gross Margin (%)	98.0	95.5	98.6	100.0	100.0
Normalised Operating Margin	578.1	-82.0	39.4	32.0	23.
BALANCE SHEET	****		****	<u> </u>	
Fixed Assets	27 121	E0 102	62 602	77 400	00.70
	27,121	50,103	63,693	77,428	98,724
Intangible Assets Tangible Assets	2,455 49	11,815 145	11,514 151	11,213 145	10,91 15
Investments & other	24,617	38,143	52,028	66,070	87,65
Current Assets	54,349	31,730	64,576	53,965	31,18
Stocks	0	0	04,570	0	31,10
Debtors	716	798	747	1,057	78:
Cash & cash equivalents	23,633	20,932	28,829	42,908	25,21
Short term liquidity investments	30,000	10,000	35,000	10,000	5,18
Current Liabilities	(631)	(1,521)	(6,698)	(7,760)	(3,730
Creditors	(631)	(1,521)	(6,698)	(7,760)	(3,730
Tax and social security	0	(1,321)	(0,090)	0	(3,730
Short term borrowings	0	0	0	0	
Other	0	0	0	0	
Long Term Liabilities	0	(271)	(217)	(163)	(109
Long term borrowings	0	0	0	0	(103
Other long-term liabilities	0	(271)	(217)	(163)	(109
Net Assets	80,839	80,041	121,354	123,470	126,06
Minority interests	0	0	0	0	120,000
Shareholders' equity	80,839	80,041	121,354	123,470	126,06
· ·	00,000	00,011	121,001	120, 110	120,000
CASH FLOW	0.040	(4.400)	0.700	0.000	0.50
Op Cash Flow before WC and tax	2,943	(1,406)	2,700	3,339	2,56
Working capital	(20)	650	5,250	(87)	(3,724
Exceptional & other	(4,952)	(1,268)	(5,107)	(3,694)	(3,916
Tax	0 (2.222)	0	0	0 (112)	(5.000
Net operating cash flow	(2,029)	(2,024)	2,843	(442)	(5,080
Capex	(27)	(113)	(82)	(75)	(92
Acquisitions/disposals	(11,563)	(20,939)	(8,779)	(10,664)	(17,673
Net interest	22	397	165	260	53
Equity financing	67,230	(22)	38,750	0	(196
Dividends	(30,000)	20,000	(25,000)	0	4.04
Other	(30,000)	20,000	(25,000)	25,000	4,81
Net Cash Flow	23,633	(2,701)	7,897	14,079	(17,698
Opening net debt/(cash)	(39)	(23,633)	(20,932)	(28,829)	(42,908
FX	0	0	0	0	
Other non-cash movements	(39)	0	0	0	(05.040
Closing net debt/(cash)	(23,633)	(20,932)	(28,829)	(42,908)	(25,210
Closing net debt/ (cash) inc short-term liquidity investments (not EIS)	(53,633)	(30,932)	(59,601)	(49,435)	(29,798



#### General disclaimer and copyright

This report has been commissioned by Mercia Asset Management and prepared and issued by Edison, in consideration of a fee payable by Mercia Asset Management. Edison Investment Research standard fees are £49,500 pa for the production and broad dissemination of a detailed note (Outlook) following by regular (typically quarterly) update notes. Fees are paid upfront in cash without recourse. Edison may seek additional fees for the provision of roadshows and related IR services for the client but does not get remunerated for any investment banking services. We never take payment in stock, options or warrants for any of our services.

Accuracy of content: All information used in the publication of this report has been compiled from publicly available sources that are believed to be reliable, however we do not guarantee the accuracy or completeness of this report and have not sought for this information to be independently verified. Opinions contained in this report represent those of the Edison analyst at the time of publication. Forward-looking information or statements in this report contain information that is based on assumptions, forecasts of future results, estimates on amounts not yet determinable, and therefore involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of their subject matter to be materially different from current expectations.

Exclusion of Liability: To the fullest extent allowed by law, Edison shall not be liable for any direct, indirect or consequential losses, loss of profits, damages, costs or expenses incurred or suffered by you arising out or in connection with the access to, use of or reliance on any information contained on this note.

No personalised advice: The information that we provide should not be construed in any manner whatsoever as, personalised advice. Also, the information provided by us should not be construed by any subscriber or prospective subscriber as Edison's solicitation to effect, or attempt to effect, any transaction in a security. The securities described in the report may not be eligible for sale in all jurisdictions or to certain categories of investors.

Investment in securities mentioned: Edison has a restrictive policy relating to personal dealing and conflicts of interest. Edison Group does not conduct any investment business and, accordingly, does not itself hold any positions in the securities mentioned in this report. However, the respective directors, officers, employees and contractors of Edison may have a position in any or related securities mentioned in this report, subject to Edison's policies on personal dealing and conflicts of interest.

Copyright: Copyright 2019 Edison Investment Research Limited (Edison). All rights reserved FTSE International Limited ("FTSE") © FTSE 2019. "FTSE®" is a trade mark of the London Stock Exchange Group companies and is used by FTSE International Limited under license. All rights in the FTSE indices and/or FTSE ratings vest in FTSE and/or its licensors. Neither FTSE nor its licensors accept any liability for any errors or omissions in the FTSE indices and/or FTSE ratings or underlying data. No further distribution of FTSE Data is permitted without FTSE's express written consent.

#### **Australia**

Edison Investment Research Pty Ltd (Edison AU) is the Australian subsidiary of Edison. Edison AU is a Corporate Authorised Representative (1252501) of Crown Wealth Group Pty Ltd who holds an Australian Financial Services Licence (Number: 494274). This research is issued in Australia by Edison AU and any access to it, is intended only for "wholesale clients" within the meaning of the Corporations Act 2001 of Australia. Any advice given by Edison AU is general advice only and does not take into account your personal circumstances, needs or objectives. You should, before acting on this advice, consider the appropriateness of the advice, having regard to your objectives, financial situation and needs. If our advice relates to the acquisition, or possible acquisition, of a particular financial product you should read any relevant Product Disclosure Statement or like instrument.

#### **New Zealand**

The research in this document is intended for New Zealand resident professional financial advisers or brokers (for use in their roles as financial advisers or brokers) and habitual investors who are "wholesale clients" for the purpose of the Financial Advisers Act 2008 (FAA) (as described in sections 5(c) (1)(a), (b) and (c) of the FAA). This is not a solicitation or inducement to buy, sell, subscribe, or underwrite any securities mentioned or in the topic of this document. For the purpose of the FAA, the content of this report is of a general nature, is intended as a source of general information only and is not intended to constitute a recommendation or opinion in relation to acquiring or disposing (including refraining from acquiring or disposing) of securities. The distribution of this document is not a "personalised service" and, to the extent that it contains any financial advice, is intended only as a "class service" provided by Edison within the meaning of the FAA (i.e. without taking into account the particular financial situation or goals of any person). As such, it should not be relied upon in making an investment decision.

#### **United Kingdom**

Neither this document and associated email (together, the "Communication") constitutes or form part of any offer for sale or subscription of, or solicitation of any offer to buy or subscribe for, any securities, nor shall it or any part of it form the basis of, or be relied on in connection with, any contract or commitment whatsoever. Any decision to purchase shares in the Company in the proposed placing should be made solely on the basis of the information to be contained in the admission document to be published in connection therewith.

This Communication is being distributed in the United Kingdom and is directed only at (i) persons having professional experience in matters relating to investments, i.e. investment professionals within the meaning of Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the "FPO") (ii) high net-worth companies, unincorporated associations or other bodies within the meaning of Article 49 of the FPO and (iii) persons to whom it is otherwise lawful to distribute it. The investment activity to which this document relates is available only to such persons. It is not intended that this document be distributed or passed on, directly or indirectly, to any other class of persons and in any event and under no circumstances should persons of any other description rely on or act upon the contents of this document (nor will such persons be able to purchase shares in the placing).

This Communication is being supplied to you solely for your information and may not be reproduced by, further distributed to or published in whole or in part by, any other person.

#### **United States**

The Investment Research is a publication distributed in the United States by Edison Investment Research, Inc. Edison Investment Research, Inc. is registered as an investment adviser with the Securities and Exchange Commission. Edison relies upon the "publishers' exclusion" from the definition of investment adviser under Section 202(a) (11) of the Investment Advisers Act of 1940 and corresponding state securities laws. This report is a bona fide publication of general and regular circulation offering impersonal investment-related advice, not tailored to a specific investment portfolio or the needs of current and/or prospective subscribers. As such, Edison does not offer or provide personal advice and the research provided is for informational purposes only. No mention of a particular security in this report constitutes a recommendation to buy, sell or hold that or any security, or that any particular security, portfolio of securities, transaction or investment strategy is suitable for any specific person.